March 16 (Reuters) - BAYER AG BAYGn.DE:
KERENDIA® (FINERENONE) MEETS PRIMARY ENDPOINT IN INVESTIGATIONAL PHASE III FIND-CKD STUDY IN PATIENTS WITH NON-DIABETIC CHRONIC KIDNEY DISEASE
DEMONSTRATING A STATISTICALLY SIGNIFICANT IMPROVEMENT VERSUS PLACEBO IN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) SLOPE FROM BASELINE TO MONTH 32 - A SURROGATE ENDPOINT FOR SLOWING KIDNEY DISEASE PROGRESSION
Further company coverage: [BAYGn.DE]